# D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer

> **NCT05212012** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AIO-Studien-gGmbH** · enrollment: 11 (actual)

## Conditions studied

- Chemo-refractory Colorectal Carcinoma

## Interventions

- **DRUG:** Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)

## Key facts

- **NCT ID:** NCT05212012
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-17
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05212012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05212012, "D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05212012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*